Pioglitazone as a novel therapeutic approach in chronic granulomatous disease

[...]corticosteroids were never administered to the patient, neither before nor during pioglitazone treatment. [...]the patient did not develop any adverse effects related to pioglitazone administration, confirming the safety of this therapeutic approach. [...]Fernandez-Boyanapalli et al6 suggest th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2016-06, Vol.137 (6), p.1913-1915.e2
Main Authors: Migliavacca, Maddalena, MD, Assanelli, Andrea, MD, Ferrua, Francesca, MD, Cicalese, Maria Pia, MD, PhD, Biffi, Alessandra, MD, PhD, Frittoli, Marta, MD, Silvani, Paolo, MD, Chidini, Giovanna, MD, Calderini, Edoardo, MD, Mandelli, Anna, MD, Camporesi, Anna, MD, Milani, Raffaella, MD, Farinelli, Giada, PhD, Nicoletti, Roberto, MD, Ciceri, Fabio, MD, Aiuti, Alessandro, MD, PhD, Bernardo, Maria Ester, MD, PhD
Format: Article
Language:English
Subjects:
Allergy and Immunology
Blood
Genes
Granulocytes
Granulomatous Disease, Chronic - drug therapy
Humans
Infant
Infections
Letter to the Editor
Male
Mortality
Mutation
Neutrophils
Pediatrics
Pioglitazone
Studies
Thiazolidinediones - administration & dosage
Tomography
Ventilation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]corticosteroids were never administered to the patient, neither before nor during pioglitazone treatment. [...]the patient did not develop any adverse effects related to pioglitazone administration, confirming the safety of this therapeutic approach. [...]Fernandez-Boyanapalli et al6 suggest that the mechanism responsible for peroxisome proliferator-activated receptor gamma agonist effect in mice with CGD is related to increased ROS production by mitochondria in a subpopulation of neutrophils, monocytes, and inflammatory macrophages.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2016.01.033